Total-Body ⁶⁸Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines.

ABSTRACT: Our purpose was to determine the relationship between serum prostate-specific antigen (PSA) level categories (<5, 5-10, 10-20, and >20 ng/mL) and the incidence of bone metastases detected by total-body ⁶⁸Ga-prostate-specific membrane antigen (PSMA)-11 PET/CT and to assess if expanding the ⁶⁸Ga-PSMA-11 PET/CT imaging field to include the vertex and lower extremities (total-body acquisition) affects bone metastasis detection rates and patient management. Methods: This was a retrospective analysis of 388 prostate cancer patients enrolled in 5 prospective studies (NCT02940262, NCT03368547, NCT03042312, NCT04050215, and NCT03515577). All underwent ⁶⁸Ga-PSMA-11 PET/CT scans acquired from vertex to toes for primary staging (n = 93/388, 24%), biochemi

SUBMITTER: Pomykala KL 

PROVIDER: S-EPMC7067527 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature